Lupin Pharma Canada is pleased to announce that ZAXINE is listed with special authority criteria as February 6, 2018.
The coverage criteria are as follows:
For reducing the risk of overt hepatic encephalopathy (HE) recurrence in patients who meet the following criteria:
- Have been hospitalized with HE associated with cirrhosis of the liver; AND
- Are unable to achieve adequate control, despite taking the maximum tolerated dose of lactulose; AND
- Rifaximin must be prescribed by an internal medicine specialist or a gastroenterologist.
Rifaximin should be used in combination with a maximal tolerated dose of lactulose.
For more information, click here